Product Description
Abiraterone is used in combination with prednisone to treat a certain type of prostate cancer that has spread to other parts of the body. Abiraterone is in a class of medications called androgen biosynthesis inhibitors. It works by decreasing the amount of certain hormones in the body.
Mechanisms of Action: CYP17A1 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Netherlands | New Zealand | Norway | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Oncology Solid Tumor Unspecified | Prostate Cancer | Oncology Unspecified | Oncology Solid Tumor Unspecified | Prostate Cancer | Oncology Unspecified
Known Adverse Events: Hypertension | Respiratory Tract Infections | Hypokalemia | Diarrhea | Dyspepsia | Edema | Nocturia | Anemia | Lymphopenia | Hypercholesterolemia | Hyperglycemia | Hypertriglyceridemia | Hypophosphatemia | Dyspnea
Company: Johnson & Johnson
Company Location: NEW BRUNSWICK NJ 08933
Company CEO: Joaquin Duato
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belarus, Belgium, Brazil, Bulgaria, Canada, Chile, China, Czech Republic, Denmark, France, Georgia, Germany, Greece, Hong Kong, Hungary, India, Israel, Italy, Japan, Korea, Malaysia, Mexico, Moldova, Netherlands, New Zealand, Peru, Philippines, Poland, Portugal, Puerto Rico, Romania, Russia, Slovakia, South Africa, Spain, Sweden, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, United States, Vietnam
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Drug Hypersensitivity|Prostate Cancer
Phase 1: Nose Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| REVELUTION-2 | P3 |
Not yet recruiting |
Prostate Cancer |
2029-07-01 |
|
| KNIGHTS | P2 |
Recruiting |
Prostate Cancer |
2028-12-31 |
|
| SHR6390-305 | P1 |
Not yet recruiting |
Prostate Cancer |
2028-12-01 |
39% |
| SHR6390-305 | P1 |
Not yet recruiting |
Prostate Cancer |
2028-12-01 |
39% |
| SHR6390-305 | P1 |
Not yet recruiting |
Prostate Cancer |
2028-12-01 |
39% |
| Maverick Trial | P2 |
Suspended |
Prostate Cancer |
2028-01-01 |
57% |
| Maverick Trial | P2 |
Suspended |
Prostate Cancer |
2028-01-01 |
57% |